StreetInsider.com News Articles

Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics

Fri, 13 Mar 2026 11:38:00 -0400

Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies
This partnership will generate revenue through:
- A computational longevity platform, including unique curated datasets and accelerated computation methods relevant for longevity research
- Next-generation drug candidates against sarcopenia
- Next generation drug candidates for dry age-related macular degeneration

SINGAPORE, PARIS and CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- Lynxkite is expanding its partnership with Biophytis SA (Euronext Growth Paris: ALBPS) ("Biophytis"), starting with the MASSIVE project (MAS Receptor Synthetic Innovation & Virtual Engineering for

Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics

Fri, 13 Mar 2026 11:38:00 -0400

Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies
This partnership will generate revenue through:
A computational longevity platform, including unique curated datasets and accelerated computation methods relevant for longevity research
Next-generation drug candidates against sarcopenia
Next generation drug candidates for dry age-related macular degeneration
SINGAPORE, PARIS and CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- Lynxkite is expanding its partnership with Biophytis SA (Euronext Growth Paris: ALBPS) ("Biophytis"), starting with the MASSIVE project (MAS Receptor Synthetic Innovation & Virtual Engineering for

Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics

Fri, 13 Mar 2026 11:38:00 -0400

Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies
This partnership will generate revenue through:
A computational longevity platform, including unique curated datasets and accelerated computation methods relevant for longevity research
Next-generation drug candidates against sarcopenia
Next generation drug candidates for dry age-related macular degeneration
SINGAPORE, PARIS and CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- Lynxkite is expanding its partnership with Biophytis SA (Euronext Growth Paris: ALBPS) ("Biophytis"), starting with the MASSIVE project (MAS Receptor Synthetic Innovation & Virtual Engineering for

Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics

Fri, 13 Mar 2026 11:38:00 -0400

Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies
This partnership will generate revenue through:
A computational longevity platform, including unique curated datasets and accelerated computation methods relevant for longevity research
Next-generation drug candidates against sarcopenia
Next generation drug candidates for dry age-related macular degeneration
SINGAPORE, PARIS and CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- Lynxkite is expanding its partnership with Biophytis SA (Euronext Growth Paris: ALBPS) ("Biophytis"), starting with the MASSIVE project (MAS Receptor Synthetic Innovation & Virtual Engineering for

Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics

Fri, 13 Mar 2026 11:38:00 -0400

Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies
This partnership will generate revenue through:
A computational longevity platform, including unique curated datasets and accelerated computation methods relevant for longevity research
Next-generation drug candidates against sarcopenia
Next generation drug candidates for dry age-related macular degeneration
SINGAPORE, PARIS and CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- Lynxkite is expanding its partnership with Biophytis SA (Euronext Growth Paris: ALBPS) ("Biophytis"), starting with the MASSIVE project (MAS Receptor Synthetic Innovation & Virtual Engineering for

Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics

Fri, 13 Mar 2026 11:38:00 -0400

Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies
This partnership will generate revenue through:
A computational longevity platform, including unique curated datasets and accelerated computation methods relevant for longevity research
Next-generation drug candidates against sarcopenia
Next generation drug candidates for dry age-related macular degeneration
SINGAPORE, PARIS and CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- Lynxkite is expanding its partnership with Biophytis SA (Euronext Growth Paris: ALBPS) ("Biophytis"), starting with the MASSIVE project (MAS Receptor Synthetic Innovation & Virtual Engineering for

Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics

Fri, 13 Mar 2026 11:38:00 -0400

Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies
This partnership will generate revenue through:
A computational longevity platform, including unique curated datasets and accelerated computation methods relevant for longevity research
Next-generation drug candidates against sarcopenia
Next generation drug candidates for dry age-related macular degeneration
SINGAPORE, PARIS and CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- Lynxkite is expanding its partnership with Biophytis SA (Euronext Growth Paris: ALBPS) ("Biophytis"), starting with the MASSIVE project (MAS Receptor Synthetic Innovation & Virtual Engineering for

Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics

Fri, 13 Mar 2026 11:38:00 -0400

Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies
This partnership will generate revenue through:
A computational longevity platform, including unique curated datasets and accelerated computation methods relevant for longevity research
Next-generation drug candidates against sarcopenia
Next generation drug candidates for dry age-related macular degeneration
SINGAPORE, PARIS and CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- Lynxkite is expanding its partnership with Biophytis SA (Euronext Growth Paris: ALBPS) ("Biophytis"), starting with the MASSIVE project (MAS Receptor Synthetic Innovation & Virtual Engineering for

Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics

Fri, 13 Mar 2026 11:38:00 -0400

Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies
This partnership will generate revenue through:
A computational longevity platform, including unique curated datasets and accelerated computation methods relevant for longevity research
Next-generation drug candidates against sarcopenia
Next generation drug candidates for dry age-related macular degeneration
SINGAPORE, PARIS and CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- Lynxkite is expanding its partnership with Biophytis SA (Euronext Growth Paris: ALBPS) ("Biophytis"), starting with the MASSIVE project (MAS Receptor Synthetic Innovation & Virtual Engineering for

Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics

Fri, 13 Mar 2026 11:38:00 -0400

Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies
This partnership will generate revenue through:
A computational longevity platform, including unique curated datasets and accelerated computation methods relevant for longevity research
Next-generation drug candidates against sarcopenia
Next generation drug candidates for dry age-related macular degeneration
SINGAPORE, PARIS and CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- Lynxkite is expanding its partnership with Biophytis SA (Euronext Growth Paris: ALBPS) ("Biophytis"), starting with the MASSIVE project (MAS Receptor Synthetic Innovation & Virtual Engineering for

Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics

Fri, 13 Mar 2026 11:38:00 -0400

Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies
This partnership will generate revenue through:
A computational longevity platform, including unique curated datasets and accelerated computation methods relevant for longevity research
Next-generation drug candidates against sarcopenia
Next generation drug candidates for dry age-related macular degeneration
SINGAPORE, PARIS and CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- Lynxkite is expanding its partnership with Biophytis SA (Euronext Growth Paris: ALBPS) ("Biophytis"), starting with the MASSIVE project (MAS Receptor Synthetic Innovation & Virtual Engineering for

Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics

Fri, 13 Mar 2026 11:38:00 -0400

Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies
This partnership will generate revenue through:
A computational longevity platform, including unique curated datasets and accelerated computation methods relevant for longevity research
Next-generation drug candidates against sarcopenia
Next generation drug candidates for dry age-related macular degeneration
SINGAPORE, PARIS and CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- Lynxkite is expanding its partnership with Biophytis SA (Euronext Growth Paris: ALBPS) ("Biophytis"), starting with the MASSIVE project (MAS Receptor Synthetic Innovation & Virtual Engineering for

Form 144 Nebius Group N.V. Filed by: Nave Ophir

Fri, 13 Mar 2026 08:45:00 -0400
si-local-file:///var/storage/secattach/20260313/26156867.html

Form 144 Nebius Group N.V. Filed by: Nave Ophir

Fri, 13 Mar 2026 08:45:00 -0400
si-local-file:///var/storage/secattach/20260313/26156867.html

Compass Point Reiterates Buy Rating on Nebius Group (NBIS) amid Nvidia investment

Wed, 11 Mar 2026 14:23:57 -0400

Compass Point analyst Michael Donovan reiterated a Buy rating and $150.00 price target on Nebius Group (NASDAQ: NBIS)
The analyst commented, "NVIDIA adds strategic validation, incremental capital, and longer-dated visibility around the capacity plan. Nebius this morning announced a broadened strategic partnership with NVIDIA that combines a $2B investment, structured as a private placement of a pre-funded warrant, with deeper collaboration across AI factory design, inference and agentic AI software, next-generation system deployment including Rubin, Vera CPUs, and BlueField storage, and fleet-health optimization. The stated goal is to support deployment of more than 5GW of NVIDIA systems by end-2030 across customers

Nebius flies as NVIDIA inks $2B cloud deal amid ’circular financing’ scrutiny

Wed, 11 Mar 2026 08:39:00 -0400

Investing.com -- Nebius Group N.V. (NASDAQ:NBIS) shares rose 10% Wednesday morning after NVIDIA announced a $2 billion investment in the cloud provider as part of a strategic partnership to develop hyperscale cloud infrastructure for the AI market.
The partnership deepens collaboration across the full AI technology stack, from AI factory architecture to production software, enabling Nebius to accelerate the buildout of its AI cloud platform. NVIDIA will support Nebius’s early adoption of the latest generation of NVIDIA’s accelerated computing platform.
Under the agreement, Nebius plans to deploy more than 5 gigawatts of capacity by the end of 2030. The

Nebius flies as NVIDIA inks $2B cloud deal amid ’circular financing’ scrutiny

Wed, 11 Mar 2026 08:39:00 -0400

Investing.com -- Nebius Group N.V. (NASDAQ:NBIS) shares rose 10% Wednesday morning after NVIDIA announced a $2 billion investment in the cloud provider as part of a strategic partnership to develop hyperscale cloud infrastructure for the AI market.
The partnership deepens collaboration across the full AI technology stack, from AI factory architecture to production software, enabling Nebius to accelerate the buildout of its AI cloud platform. NVIDIA will support Nebius’s early adoption of the latest generation of NVIDIA’s accelerated computing platform.
Under the agreement, Nebius plans to deploy more than 5 gigawatts of capacity by the end of 2030. The

Nebius flies as NVIDIA inks $2B cloud deal amid ’circular financing’ scrutiny

Wed, 11 Mar 2026 08:39:00 -0400

Investing.com -- Nebius Group N.V. (NASDAQ:NBIS) shares rose 10% Wednesday morning after NVIDIA announced a $2 billion investment in the cloud provider as part of a strategic partnership to develop hyperscale cloud infrastructure for the AI market.
The partnership deepens collaboration across the full AI technology stack, from AI factory architecture to production software, enabling Nebius to accelerate the buildout of its AI cloud platform. NVIDIA will support Nebius’s early adoption of the latest generation of NVIDIA’s accelerated computing platform.
Under the agreement, Nebius plans to deploy more than 5 gigawatts of capacity by the end of 2030. The

Nebius flies as NVIDIA inks $2B cloud deal amid ’circular financing’ scrutiny

Wed, 11 Mar 2026 08:39:00 -0400

Investing.com -- Nebius Group N.V. (NASDAQ:NBIS) shares rose 10% Wednesday morning after NVIDIA announced a $2 billion investment in the cloud provider as part of a strategic partnership to develop hyperscale cloud infrastructure for the AI market.
The partnership deepens collaboration across the full AI technology stack, from AI factory architecture to production software, enabling Nebius to accelerate the buildout of its AI cloud platform. NVIDIA will support Nebius’s early adoption of the latest generation of NVIDIA’s accelerated computing platform.
Under the agreement, Nebius plans to deploy more than 5 gigawatts of capacity by the end of 2030. The

Form 6-K Nebius Group N.V. For: Mar 11

Wed, 11 Mar 2026 08:15:00 -0400
si-local-file:///var/storage/secattach/20260311/26143017.html

Form 6-K Nebius Group N.V. For: Mar 11

Wed, 11 Mar 2026 08:15:00 -0400
si-local-file:///var/storage/secattach/20260311/26143017.html

NVIDIA invests $2 billion in cloud provider Nebius

Wed, 11 Mar 2026 08:02:18 -0400
(Updated - March 11, 2026 8:02 AM EDT)
NVIDIA Corp. (NASDAQ: NVDA) announced a $2 billion investment in Nebius Group N.V. (NASDAQ: NBIS) as part of a strategic partnership to develop cloud infrastructure for artificial intelligence applications, according to a company statement.
The partnership aims to support Nebius in expanding its AI cloud platform to meet growing demand for high-performance computing. Under the agreement, Nebius plans to deploy more than 5 gigawatts of capacity by the end of 2030, with NVIDIA providing early access to its latest computing platforms.
The collaboration includes AI factory design support, inference technology development, infrastructure deployment across multiple

NVIDIA invests $2 billion in cloud provider Nebius

Wed, 11 Mar 2026 08:02:18 -0400
(Updated - March 11, 2026 8:02 AM EDT)
NVIDIA Corp. (NASDAQ: NVDA) announced a $2 billion investment in Nebius Group N.V. (NASDAQ: NBIS) as part of a strategic partnership to develop cloud infrastructure for artificial intelligence applications, according to a company statement.
The partnership aims to support Nebius in expanding its AI cloud platform to meet growing demand for high-performance computing. Under the agreement, Nebius plans to deploy more than 5 gigawatts of capacity by the end of 2030, with NVIDIA providing early access to its latest computing platforms.
The collaboration includes AI factory design support, inference technology development, infrastructure deployment across multiple

NVIDIA invests $2 billion in cloud provider Nebius

Wed, 11 Mar 2026 08:02:18 -0400
(Updated - March 11, 2026 8:02 AM EDT)
NVIDIA Corp. (NASDAQ: NVDA) announced a $2 billion investment in Nebius Group N.V. (NASDAQ: NBIS) as part of a strategic partnership to develop cloud infrastructure for artificial intelligence applications, according to a company statement.
The partnership aims to support Nebius in expanding its AI cloud platform to meet growing demand for high-performance computing. Under the agreement, Nebius plans to deploy more than 5 gigawatts of capacity by the end of 2030, with NVIDIA providing early access to its latest computing platforms.
The collaboration includes AI factory design support, inference technology development, infrastructure deployment across multiple

NVIDIA invests $2 billion in cloud provider Nebius

Wed, 11 Mar 2026 08:02:18 -0400
(Updated - March 11, 2026 8:02 AM EDT)
NVIDIA Corp. (NASDAQ: NVDA) announced a $2 billion investment in Nebius Group N.V. (NASDAQ: NBIS) as part of a strategic partnership to develop cloud infrastructure for artificial intelligence applications, according to a company statement.
The partnership aims to support Nebius in expanding its AI cloud platform to meet growing demand for high-performance computing. Under the agreement, Nebius plans to deploy more than 5 gigawatts of capacity by the end of 2030, with NVIDIA providing early access to its latest computing platforms.
The collaboration includes AI factory design support, inference technology development, infrastructure deployment across multiple